<DOC>
	<DOCNO>NCT01580553</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety L-carnitine injection treatment Chinese patient heart failure . A prospective , multicenter , randomize , double-blind , parallel , placebo-controlled clinical study perform . Treatment period : 7 day , follow-up : 1 month</brief_summary>
	<brief_title>The Clinical Study Efficacy Safety L-Carnitine Injection Treatment Heart Failure</brief_title>
	<detailed_description>The primary objective study assess efficacy safety L-carnitine injection treatment Chinese patient heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . The subject age ≥ 18 year , men woman . 2 . The subject diagnosis chronic leave heart right heart failure ( past medical history leave heart failure cause coronary heart disease , hypertension dilate cardiomyopathy , medical history right heart failure cause pulmonary artery hypertension ( 1st type diagnostic classification , WHO conference , Venice , 2003 ) leave heart disease ( 2nd type ) ; case number right heart failure 30 % total case number ) . 3 . The subject need hospitalization heart failure stay hospital 7 day . 4 . NYHAFC Class II IV ( Class II case ＜ 20 % , except refractory terminal heart failure patient ) . 5 . The subject 's UCG show LVEF ≤ 45％ ( left heart failure ) . 6 . CI &lt; 2.5 L/min/m2 CO ＜ 4L/min ( right heart failure ) 7 . The subject sign ICF . 1 . Subjects medical history heart failure cause valvular heart disease , mechanical obstruction , pericardial disease myocardial amyloidosis . 2 . Subjects heart function Class IV unstable hemodynamics need final stage cardiac transplantation intravenous vasoactive drug . 3 . Subjects leave hospital 7 day . 4 . Subjects severe cerebral apoplexy ( life threaten ) . 5 . Subjects AMI acute pulmonary embolism . 6 . Subjects uremia undergo dialysis . 7 . Subjects COPD . 8 . Subjects severe anemia ( Hb≤60g/l ) . 9 . Subject receive metabolism improve drug within one month ( trimetazidine dihydrochloride tablet 1 , 6 fructose diphosphate . 10 . Subject severe disease his/her life expectancy ＜12 month . 11 . Subject participate clinical trial within 3 month participate study . 12 . Subject receive Lcarnitine treatment within 1 month . 13 . Subject allergic Lcarnitine derivative . 14 . Subject receive cardiotoxic drug . 15 . Subjects medical history epilepsy . 16 . Subject drug alcohol abuser . 17 . Subject receive PCI , CABG vascular remodel . 18 . Subject arrhythmia investigator think unsuitable include . 19 . The subject pregnant lactating , woman childbearing age take contraception measure . 20 . The subject sign ICF .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>L-carnitine</keyword>
	<keyword>injection</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>